«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年02期

页码:

229-233

栏目:

论著

出版日期:

2024-04-20

文章信息/Info

Title:

Analysis of imaging and clinical features of patients with pulmonary aspergillosis

作者:

游雅婷; 刘 熙; 白 莉; 郭 亮

400037 重庆,陆军(第三)军医大学第二附属医院呼吸与危重症医学科

Author(s):

You Yating;  Liu Xi;  Bai Li;  Guo Liang.

Institute of Respiratory Disease, The Second Affiliated Hospital(Xinqiao Hospital), Army Medical University, Chongqing, China

关键词:

肺曲霉菌病;  影像学;  临床特征

Keywords:

Pulmonary aspergillosis;  Imaging;  Clinical features

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2024.02.011

摘要:

目的 分析有或无基础疾病患肺曲霉菌病(pulmonary aspergillosis)的流行病学,早期识别肺曲霉菌病患者的特征,以指导临床诊疗。方法 回顾性分析2020年9月至2022年7月我院收治的肺曲霉菌病患者39例为对象,分无基础疾病为观察组17例和有基础疾病组为对照组22例,收集患者的性别、年龄、职业; 症状,糖皮质激素使用史,抗生素使用史,胸部影像学特征及实验室检查,包括血常规、血沉、肝功能、肾功能、凝血功能、D-二聚体,比较两组数据。结果 39例肺曲霉菌病患者中,年龄大于60岁观察组3例(17.65%),对照组13例(59.09%)(P<0.05); 糖皮质激素使用史对照组7例(31.82%),观察组17例中无使用者(P<0.05); 胸部影像不规则高密度影观察组7例(41.18%),对照组17例(77.27%)(P<0.05); 肺部单侧病变观察组13例(76.47%),对照组7例(31.82%)(P<0.05); 观察组尿素氮5.58[3.85～6.3]mmol/L,D-二聚体0.14[0.08～0.44]mg/L低于对照组6.67[5.09～10.53]mmol/L,0.73(0.26～1.17)mg/L(P<0.05); 观察组血红蛋白130.00(124.00～134.00)g/L,总蛋白(69.60±7.41)g/L,白蛋白40.90(33.15～43.75)g/L高于对照组106.00(85.75～117.00)g/L,(58.90±9.45)g/L,31.70(27.93～38.93)g/L(P<0.05)。结论 肺曲霉菌病可发生在肺部单侧,以肺结节、肺空洞及不规则高密度阴影表现; 高龄、尿素氮、血红蛋白、总蛋白、白蛋白水平和D二聚体浓度是区别有无基础疾病患肺曲霉菌病的主要因素。

Abstract:

Objective To analyze the epidemiological characteristics of pulmonary aspergillosis(PA)with or without underlying diseases, and to early identify the characteristics of pulmonary aspergillosis without underlying diseases to guide clinical diagnosis and treatment. Method A total of 39 patients with pulmonary aspergillosis admitted to our hospital from September 1, 2020 to July 1, 2022 were retrospectively analyzed. They were divided into the observation group 17 cases without underlying diseases and the control group 22 cases with underlying diseases. The gender, age, occupation, symptoms, history of glucocorticoid use, history of antibiotic use, chest imaging characteristics and laboratory examination of the patients were collected. Including blood routine, erythrocyte sedimentation rate, liver function, renal function, coagulation function, D-dimer, the two groups were statistically analyzed. Result Among the 39 patients with pulmonary aspergillosis, there were 3 cases(17.65%)in the observation group and 13 cases(59.09%)in the control group aged over 60 years(P<0.05). There were 7 cases(31.82%)of glucocorticoid use history in the control group, and no cases in the observation group, the difference between the two groups was statistically significant(P=0.012). There were 7 cases(41.18%)of irregular high density shadow in the observation group and 17 cases(77.27%)in the control group(P<0.05). There were 13 cases(76.47%)in the observation group and 7 cases(31.82%)in the control group with unilateral lung lesions(P<0.05). Blood urea nitrogen 5.58[3.85-6.3]mmol/L in the observation group, 6.67[5.09-10.53]mmol/L in the control group(P<0.05), D-dimer 0.14[0.08-0.44]mg/L in the observation group, 0.73(0.26-1.17)mg/L in the control group, the difference was statistically significant(P<0.05). The difference between the two groups was statistically significant(P<0.05). Hemoglobin was 130.00(124.00-134.00)g/L in the observation group and 106.00(85.75-117.00)g/L in the control group(P<0.05). Total protein was(69.60±7.41)g/L in the observation group and(58.90±9.45)g/Lin the control group(P<0.05). Albumin was 40.90(33.15-43.75)g/L in the observation group and 31.70(27.93-38.93)g/L in the control group(P<0.05). Conclusions Pulmonary aspergillosis can occur in one side of the lung, pulmonary nodules, pulmonary cavities and irregular high-density shadows. Advanced age, blood urea nitrogen, hemoglobin, total protein levels, albumin levels and D-dimer are the main factors to distinguish pulmonary aspergillosis with or without underlying diseases.

参考文献/References:

1 任之栋, 张 巧, 张玉江, 等. 慢性阻塞性肺疾病合并慢性肺曲霉菌病的高危因素及临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(1): 11-16.
2 Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients[J]. Intensive Care Med,2017, 43: 1225-1238.
3 Paramythiotou E, Frantzeskaki F, Flevari A, et al. Invasive fungal infections in the ICU: how to approach, how to treat[J]. Molecules, 2014, 19: 1085-1119.
4 Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, et al. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients[J]. Intensive Care Med, 2007, 33: 1694-1703.
5 Denning DW. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024: S1473-3099(24)00103-8.
6 Ao Z, Xu H, Li M, et al. Clinical characteristics, diagnosis, outcomes and lung microbiome analysis of invasive pulmonary aspergillosis in the community-acquired pneumonia patients[J]. BMJ Open Respir Res, 2023, 10(1): e001358.
7 Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery[J]. J Clin Oncol, 1997, 15(1): 139-147.
8 Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis[J]. Eur Respir J, 2017,49(2): 1602520.
9 Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis[J]. Clin Infect Dis, 2008, 47(9): 1176-1184.
10 Bulpa P, Duplaquet F, Dimopoulos G, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations[J]. Semin Respir Crit Care Med, 2020, 41(6): 851-861.
11 Chotirmall SH, Martin-Gomez MT. Aspergillus species in bronchiectasis:Challenges in the cystic fibrosis and non-cystic fibrosis airways[J]. Mycopathologia, 2018, 183(1): 45-59.
12 Tudesq JJ, Peyrony O, Lemiale V, et al. Invasive pulmonary aspergillosis in nonimmunocompromised hosts[J]. Semin Respir Crit Care Med, 2019, 40(4): 540-547.
13 Bouza E, Guinea J, Pelaez T, et al. Workload due to aspergillus fumigatus and signifcance of the organism in the microbiology laboratory of a general hospital[J]. J Clin Microbiol, 2005, 43(5): 2075-2079.
14 Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients[J]. Clin Infect Dis, 2020, 70(5): 723-730.
15 Godoy MCB, Ferreira Dalla Pria HR, Truong MT,et al. Invasive fungal pneumonia in immunocompromised patients[J]. Radiol Clin North Am, 2022, 60(3): 497-506.
16 Dandachi D, Wilson Dib R, Fernández-Cruz A, et al. Invasive pulmonary aspergillosis in patients with solid tumours: Risk factors and predictors of clinical outcomes[J]. Ann Med, 2018, 50(8): 713-720.
17 Lao M, Li C, Li J, et al. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: Clinical features and associated factors[J]. J Diabetes Investig, 2020, 11(3): 731-744.
18 Feng C, Zhang M, Zhang S, et al. Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice[J]. BMC Pulm Med, 2021, 21(1): 31.
19 Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study[J]. Lancet Respir Med, 2018, 6(10): 782-792.
20 Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together[J]. Curr Opin Crit Care, 2019, 25(5): 430-437.
21 陈 虎, 陈 亮, 杨 健, 等. 免疫正常宿主侵袭性气管支气管曲霉病一例[J]. 中国呼吸与危重监护杂志, 2019, 18(6): 581-583.
22 Otu A, Kosmidis C, Mathioudakis AG, et al. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease[J]. Infection, 2023, 51(4): 813-829.
23 Zhong H, Wang Y, Gu Y, et al. Clinical features, diagnostic test performance, and prognosis in different subtypes of chronic pulmonary aspergillosis[J]. Front Med(Lausanne), 2022, 9: 811807.
24 Allwood BW, Byrne A, Meghji J, et al. Post-tuberculosis lung disease:Clinical review of an under-recognised global challenge[J]. Respiration, 2021, 100(8): 751-763.
25 Pakpoom P, Methee C. Chronic pulmonary aspergillosis following nontuberculous mycobacterial infections: An emerging disease[J]. J Fungi(Basel), 2020, 6(4): 346.
26 胡 群, 卓惠长, 徐礼裕, 等. 吸入糖皮质激素致侵袭性肺曲霉病一例[J]. 中华结核和呼吸杂志, 2016, 39(6): 480-481.
27 Raju S, Ghosh S, Mehta AC. Chest CT signs in pulmonary disease: A pictorial review[J]. Chest, 2017, 151(6): 1356-1374.
28 Caillot D, Mannone L, Cuisenier B, et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients[J]. Clin Microbiol Infect, 2001, 7(Suppl 2): 54-61.
29 Bulpa P, Bihin B, Dimopoulos G, et al. Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD?[J]. Eur Respir J, 2017, 50(3): 1700532.
30 Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome[J]. Clin Microbiol Infect, 2010, 16(7): 870-877.

备注/Memo

备注/Memo:

基金项目: 重庆市自然科学基金(CSTB2023NSCQ-MSX0936) 通信作者: 白 莉, Email: blpost@126.com 郭 亮, Email: guol1986@tmmu.edu.cn

常用功能

更新日期/Last Update: 2024-04-20